{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:22:05Z","timestamp":1762917725657,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jns.2016.11.029","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T07:31:23Z","timestamp":1479195083000},"page":"57-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Treatment of blepharospasm with apraclonidine"],"prefix":"10.1016","volume":"372","author":[{"given":"Dhanya","family":"Vijayakumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhashie","family":"Wijemanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2016.11.029_bb0005","first-page":"35","article-title":"Alpha-2 adrenergic agonists in the treatment of glaucoma","volume":"47","author":"Apatachioae","year":"1999","journal-title":"Oftalmologia"},{"key":"10.1016\/j.jns.2016.11.029_bb0010","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/bjo.79.12.1098","article-title":"Long term effect of apraclonidine","volume":"79","author":"Araujo","year":"1995","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jns.2016.11.029_bb0015","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1001\/archopht.121.8.1201","article-title":"The utility of 0.5% apraclonidine in the diagnosis of horner syndrome","volume":"121","author":"Brown","year":"2003","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jns.2016.11.029_bb0020","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/archopht.1995.01100030047020","article-title":"Clinical experience with the long-term use of 1% apraclonidine","volume":"113","author":"Butler","year":"1995","journal-title":"Incidence of allergic reactions. Archives of ophthalmology"},{"issue":"270","key":"10.1016\/j.jns.2016.11.029_bb0025","first-page":"273","article-title":"Pharmacologic reversal of Horner's syndrome-related ptosis with apraclonidine","volume":"86","author":"Chu","year":"2007","journal-title":"Ear Nose Throat J."},{"key":"10.1016\/j.jns.2016.11.029_bb0030","series-title":"Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial Spasm. Tremor and Other Hyperkinetic Movements","first-page":"338","volume":"5","author":"Dashtipour","year":"2015"},{"key":"10.1016\/j.jns.2016.11.029_bb0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.survophthal.2006.10.003","article-title":"Botulinum toxin in ophthalmology","volume":"52","author":"Dutton","year":"2007","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.jns.2016.11.029_bb0040","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jns.2014.08.004","article-title":"IncobotulinumtoxinA (Xeomin(R)) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated","volume":"346","author":"Evidente","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2016.11.029_bb0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.iop.0000196322.05586.6a","article-title":"Effect of 0.5% apraclonidine on ptosis in Horner syndrome","volume":"22","author":"Garibaldi","year":"2006","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"10.1016\/j.jns.2016.11.029_bb0050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"year":"2016","series-title":"Blepharospasm","author":"Jankovic","key":"10.1016\/j.jns.2016.11.029_bb0055"},{"key":"10.1016\/j.jns.2016.11.029_bb0060","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.22368","article-title":"Relationship between various clinical outcome assessments in patients with blepharospasm","volume":"24","author":"Jankovic","year":"2009","journal-title":"Movement disorders : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.jns.2016.11.029_bb0065","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00702-014-1278-z","article-title":"Blepharospasm: long-term treatment with either Botox(R), Xeomin(R) or Dysport(R)","volume":"122","author":"Kollewe","year":"2015","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jns.2016.11.029_bb0070","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fnins.2016.00226","article-title":"Edrophonium challenge test for blepharospasm","volume":"10","author":"Matsumoto","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jns.2016.11.029_bb0075","first-page":"1318","article-title":"Comparison of apraclonidine and timolol in chronic open-angle glaucoma","volume":"100","author":"Nagasubramanian","year":"1993","journal-title":"A three-month study. Ophthalmology"},{"key":"10.1016\/j.jns.2016.11.029_bb0080","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.toxicon.2014.07.009","article-title":"Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up","volume":"90","author":"Ramirez-Castaneda","year":"2014","journal-title":"Toxicon"},{"key":"10.1016\/j.jns.2016.11.029_bb0085","doi-asserted-by":"crossref","DOI":"10.5070\/D306G8W0MC","article-title":"The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face","volume":"11","author":"Scheinfeld","year":"2005","journal-title":"Dermatology online journal"},{"key":"10.1016\/j.jns.2016.11.029_bb0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3111\/13696998.2011.653726","article-title":"Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia","volume":"15","author":"Sethi","year":"2012","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jns.2016.11.029_bb0095","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/mds.20919","article-title":"Relative risk of spread of symptoms among the focal onset primary dystonias","volume":"21","author":"Weiss","year":"2006","journal-title":"Movement disorders : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.jns.2016.11.029_bb0100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/IOP.0b013e31817f526a","article-title":"Use of 0.5% apraclonidine solution in evaluation of blepharoptosis","volume":"24","author":"Yazici","year":"2008","journal-title":"Ophthal. Plast. Reconstr. Surg."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X1630733X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X1630733X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T03:38:19Z","timestamp":1656041899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X1630733X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":20,"alternative-id":["S0022510X1630733X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2016.11.029","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of blepharospasm with apraclonidine","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2016.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}